ABBV vs BAC: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Bank of America Corporation — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C High Quality
VS
Bank of America Corporation · Financial Services
$52.54
+7.3% upside to fair value
Grade B+
QuantHub Verdict
BAC has more upside to fair value (+7.3%). BAC trades at a lower forward P/E (12.1x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV BAC
Current Price $208.05 $52.54
Fair Value Estimate $217.50 $56.39
Upside to Fair Value +4.5% +7.3%
Market Cap $367.9B $377.1B
Forward P/E 14.9x 12.1x
EV / EBITDA 16.7x 12.8x
Price / Sales 6.1x 2.0x
Price / FCF 20.9x 29.9x
Revenue Growth YoY +8.6% -0.5%
Gross Margin 83.7% 56.1%
Operating Margin 34.7% 19.7%
Return on Equity -129.24% 10.1%
Dividend Yield 3.2% 2.09%
FCF Yield 4.78% 3.35%
Analyst Consensus Buy Buy
Investment Thesis
ABBV — AbbVie Inc.
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
BAC — Bank of America Corporation
Bank of America is a top-two U.S. bank by assets with $3.4 trillion on its balance sheet, generating $30.5 billion in net income in 2025 on the back of 12.5% earnings growth. The bank benefits from scale in consumer deposits, a recovering investment banking franchise, and an expanding digital platform serving 47 million active users. At 12.7x trailing earnings and 1.97x sales, BAC trades at a fai…
Accumulation Zones
Metric ABBV BAC
Zone Low $163.13 $42.29
Zone High $184.88 $47.93
In Buy Zone? No No
← ABBV Research    BAC Research →    All Research